A share price of Beta Bionics Inc [BBNX] is currently trading at $17.04, up 1.97%. An important factor to consider is whether the stock is rising or falling in short-term value. The BBNX shares have gain 15.60% over the last week, with a monthly amount glided 29.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beta Bionics Inc [NASDAQ: BBNX] stock has seen the most recent analyst activity on June 16, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $26. Previously, Lake Street started tracking the stock with Buy rating on June 12, 2025, and set its price target to $30. On May 30, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $20 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $16 on May 30, 2025. Stifel initiated its recommendation with a Buy and recommended $25 as its price target on February 24, 2025. Piper Sandler started tracking with a Overweight rating for this stock on February 24, 2025, and assigned it a price target of $26. In a note dated February 24, 2025, Leerink Partners initiated an Outperform rating and provided a target price of $28 on this stock.
Beta Bionics Inc experienced fluctuations in its stock price throughout the past year between $8.89 and $24.50. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $17.04 at the most recent close of the market. An investor can expect a potential drop of -0.23% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
Trailing Twelve Months sales for Beta Bionics Inc [NASDAQ:BBNX] were 78.02M which represents 54.45% growth. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.8%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -0.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.41 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.63 points at the first support level, and at 16.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.30, and for the 2nd resistance point, it is at 17.56.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Beta Bionics Inc [NASDAQ:BBNX] is 14.68. On the other hand, the Quick Ratio is 13.79, and the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 9.49, the price to book ratio is 2.46.
Transactions by insiders
Recent insider trading involved Sean Saint, Officer, that happened on Jun 02 ’25 when 3439.0 shares were purchased. Chief Commercial Officer, Hopman Mark completed a deal on Jun 02 ’25 to sell 868.0 shares. Meanwhile, Chief Medical Officer Russell Steven Jon sold 1039.0 shares on Jun 02 ’25.
